New treatments for cancer that leverage our own immune systems to attack and destroy cancer cells provide long-term, durable therapeutic responses and, in an increasing number of cases, are achieving cures in patients suffering from life-threatening cancers.
These benefits for patients have been powered by recently developed therapeutic antibodies binding with high specificity to drug targets on immune and cancer cells.
We have nine immuno-oncology projects in our pipeline and will add to this during 2016 as we explore four main therapeutic modalities:
- activation of anti-tumour NK- and T-cell activity;
- activation of macrophages to destroy cancer cells;
- depletion of immune-suppressor cells;
- increasing T-cell invasion into the tumour microenvironment.
Our approach and our portfolio are underpinned by our leading Kymouse™ platform and our strong partnerships with centres of excellence, such as the M D Anderson Cancer Center, that enhance target selection and our ability to deliver innovative new antibody based therapies including next generation bi-specific antibodies or a new class of immunocytokines.
In particular, our technology platforms are especially effective in the discovery and development of antibodies for cancer immunotherapy for the following reasons:
- Kymab believes that its Kymouse™ platform generates the largest antibody diversity of all available discovery systems, an important feature in the discovery of rare pharmacologically active molecules;
- Kymouse™ antibodies display long CDR3 loop lengths, which are essential in binding deeply buried epitopes of many drug targets;
- our discovery platform is able to create genetic knock-outs of selected target genes, vital in developing antibodies directed against a broad range of surface epitopes particularly on conserved targets.